

Figure 1

A. ctc aac cag tcc att gtc ca  
B. tcc cgg ttg ctc tga gac at  
C. gcc aca gtc atg ccc gtc ag  
D. ctg cga tcc gac tca cca at  
E. agt cct gtt ctc ttc cac  
F. ctt tac tgc tgc cat ggg  
G. cgc cgt tct cct gga tcc aa  
H. ctg act cca gct gta tcc  
I. ggt ctc cat ctc cga ttc  
J. cct ggg gtg atg tgg agc  
K. agt tcc aca aaa gta tcc  
L. ctt tcg gct ctc ggc tgc  
M. aac cag cgg ttg aag cgt

## Figure 2A

- A. (T31028)  
c\*t\*c\* aac\* cag t\*c\*c at\*t gt\*c\* c\*a
- A' . (T31029)  
C\*T\*C\* aaC\* Cag T\*C\*C aT\*T gT\*C\* C\*a
- B. (T31030)  
t\*c\*c\* cgg t\*tg c\*t\*c\* tga ga\*c\* a\*t
- C. (T31044)  
g\*c\*c\* aca gt\*c atg c\*c\*c gt\*c\* a\*g
- C' . (T31045)  
g\*C\*C\* aCa gT\*C aTg C\*C\*C gT\*C\* a\*g
- D. (T31049)  
CT\*g Cga T\*C\*C gaC\* T\*Ca C\*C\*a\* a\*t
- E. (T31054)  
a\*g\*t\* c\*c\*t gt\*t c\*t\*c t\*t\*c\* c\*a\*c
- E' . (T31055)  
a\*g\*T\* C\*C\*C\* g\*T\*T C\*T\*C T\*T\*C\* C\*a\*c
- F. (T31061)  
C\*T\*T\* TaC TgC\* TgC\* CaT\* g\*g\*g
- G. (T31043)  
C\*gC\* C\*gT\* T\*C\*T\* C\*C\*T gga TC\*C\* a\*a
- G' . (T31042)  
c\*gc\* c\*gt\* t\*c\*t\* c\*c\*t gga tc\*c\* a\*


Figure 2B

- H. (T31053)  
C\*T\*g\* aC\*T\* C\*Ca gC\*T gTa\* T\*C\*c
- H' . (T31052)  
c\*t\*g\* ac\*t\* c\*ca gc\*t gta\* t\*c\*c
- I. (T31057)  
g\*g\*T\* CT\*C\* CaT\* CT\*C Cga\* T\*T\*c
- I' . (T31056)  
g\*g\*t\* ct\*c\* cat\* ct\*c cga\* t\*t\*c
- J. (T31062/63)  
c\*c\*t\* ggg gtg\* atg\* tgg\* a\*g\*c
- K. (T31065)  
a\*g\*T\* TC\*C aC\*a aaa gT\*a\* T\*C\*c
- K' . (T31064)  
a\*g\*t\* tc\*c ac\*a aaa gt\*a\* t\*c\*c
- L. (T31067)  
C\*T\*T\* Tcg gC\*T C\*T\*C ggC\* T\*g\*c
- L' (T31066)  
c\*t\*t\* tcg gc\*t c\*t\*c ggc\* t\*g\*c
- M. (T31069)  
a\*a\*C\* Cag Cgg T\*Tg aag\* C\*g\*t
- M' . (T31068)  
a\*a\*c\* cag cgg t\*t\*g aag\* c\*g\*t

where \* = phosphorothioate  
C = Propynyl dC  
T = Propynyl dT


4/22

Figure 3A



Hydroxylamine  
MOMI  
MMI

<u>X</u>	<u>Y</u>
N-H	O
O	N-CH <sub>3</sub>
N-CH <sub>3</sub>	O





Morpholine-carbamate

09753459 040294


5/22

Figure 3B




6/22

Figure 3C



PNA dimer



Carbonate  
5'-N-carbamate


X  
O  
O

Y  
O  
NH

102070 594560

7122

Figure 3D



Formacetal

5' -Thioether

3' -Thioformacetal

5' -Thioformacetal

X

O

CH<sub>2</sub>

S

O

Y

O


S

O

S

8/22

Figure 4




X = BIOTIN  
= CHOLIC ACID  
= FLUORESCCEIN

2'-O-(AMINOPENTYL) ADENINE  
CONJUGATES




[illegible]


Figure 5A




### 3-DEAZAGUANINES




N2-IMIDAZOLYLPROPYL  
GUANINE



## 6-AZATHYMIDINE




**5,6-DIMETHYLTHYMIDINE**




6-AZA-DEOXYCYTIDINE

10/22


Figure 5B




TRIFLUOROTHYMININE



6-METHYLTHYMININE




IDOACETAMIDOPROPYL URACIL



N2-ANTRACENYLMETHYL  
GUANINE

**FIGURE 6** Effect of 18-mer PS oligonucleotides on bcl-xL protein expression in LNCaP cells



12/22

FIGURE 7

# LNCaP cell line







FIG. 8

Antisense Oligonucleotides to Bcl-xL mRNA



**FIG. 9**

# Regulation of Bcl-Family Proteins with 2'-O-Methyl - Modified PS Oligonucleotides in T24 Cell Line



**Delivery: 1 uM oligo, 5 ug/ml Lipofectin**


FIG. 10

The Most Active Chimeric PS-PO Oligonucleotides by  
Their Ability to Down-Regulate Bcl-xL Protein Expression

#	5'-	-3'
29	C*T*C* a a C* C a g T*C*C a T*T g T*C* C*a	
41	C T*g* C g a T*C*C g a C* T*C a C*C*a* a*t	
43	C*g C* C*g T* T*C*T* C*C*T g g a T C *C* a*a	
57	g*g*T* C T *C* C a T* C T*C C g a *T*T*c	
61	C*T*T* T a C T g C* T g C* C a T* g*g*g*	
62	c*c*t* <u>g g g</u> g t g* a t g* t g g* a*g*c	
63	C*C*T* <u>g g g</u> g T g* a T g* t g g* a*g*	
	C, T - propynyl modified bases, * - PS	

FIG. 11

# Regulation of Bcl-Family Proteins with 2'-O-Methyl - Modified PS Oligonucleotides in PC - 3 Cell Line




Delivery: 1uM oligo, 5 uM TMP



FIG. 12


Regulation of Bcl-xL and Bax Proteins  
with 2'-O-Methyl-Modified PS Oligonucleotides  
in LNCaP Cell Line



Delivery: 1 uM oligo, 5 uM An

FIG. 13


# Down-Regulation of Bcl-Family Proteins Expression with PS-PO Oligonucleotides in LNCaP Cell Line



Delivery: 1uM oligo, 3 uM An

FIG. 14


# Down-Regulation of Bcl-Family Proteins Expression with PS-PO Oligonucleotides in PC3 Cell Line



Delivery: 2 uM oligo, 7 uM TMP

FIG. 15

# Regulation of Bcl-Family Proteins with PS-PO Oligonucleotides in T24 Cell Line



Delivery: 0.5  $\mu$ M oligo, 5 mg/ml lipofectin

FIG. 16

# Down-Regulation of Bcl-xL mRNA with PS-PO Oligonucleotides in T24 Cell Line





FIG. 17

# Regulation of Bcl-Family Proteins with PS-PO Oligonucleotides in LNCaP Cell Line



Delivery: 1 uM oligo, 3 uM An